Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

著者: Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien, Sarah V. Gerhart, Lorna H. Mitchell, Nicholas D. Adams, Nathalie Rioux, Trupti Lingaraj, Scott Ribich, Melissa B. Pappalardi, Niyant Shah, Jenny Laraio, Yan Liu, Michael Butticello, Chris Carpenter, Caretha L. Creasy, Susan Korenchuk, Michael T. McCabe, Charles F. McHugh, Raman P. Nagarajan, Craig D. Wagner, Francesca Zappacosta, Roland S. Annan, N.O. Concha, Roberta Thomas, Timothy K. Hart, J. Joshua Smith, Robert A. Copeland, Mikel P. Moyer, John Campbell, Kim Stickland, James E. Mills, Suzanne Jacques-O’Hagan, Christina J. Allain, Danielle Johnston, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Kerren K. Swinger, Ann Boriack-Sjodin, Tom Riera, Gideon Shapiro, Richard Chesworth, Rabinder Prinjha, Ryan G. Kruger, Olena Barbash, Helai P. Mohammad - Cancer Cell 2019 被引用: 347